API
< Back to all clusters
[HEALTH] · United States · 2 sources

started · updated

Roswell Park researchers identify window for prostate cancer immunotherapy

Researchers at the Roswell Park Comprehensive Cancer Center have discovered a critical window of opportunity to enhance immunotherapy effectiveness in prostate cancer patients. A study led by Dr. Kent Nastiuk, published in the Journal for Immunotherapy for Cancer, reveals that hormonal anti-androgen therapy (ADT) temporarily activates the body’s immune response.

By analyzing tumors from men receiving ADT prior to surgery, the multidisciplinary team found that immune and inflammatory pathways—specifically antigen presentation and adaptive immune response—increased within months of starting ADT. This process activates tumor-killing cytotoxic lymphocytes that cluster near tumor cells.

However, the study also noted that these effects fade over time. After six months of ADT, inhibitory immune cells increased significantly while cytotoxic lymphocytes decreased. This shift explains why patients resistant to standard anti-androgen therapies often show resistance to immunotherapies. The findings suggest a potential new treatment strategy: using ADT to activate the immune landscape and then rapidly following up with immunotherapy before the inhibitory effects take hold.

Entities

Journal for Immunotherapy for Cancer · Kent Nastiuk · Roswell Park Comprehensive Cancer Center